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HLA-DR2 and Sleep Onset REM 
Periods in Depression 
To the Editor: 
Virtually all patients with narcolepsy/cataplexy are 
HLA-DR2 positive, in contrast o an approximately 
25% incidence of this human leukocyte antigen (HLA) 
in the general population (cf. Honda and Juji !988). 
Given the close association between arcolepsy and 
HLA-DR2 on the one hand, and the most ypical sleep 
alteration, i.e., sleep onset rapid eye movement (REIvl) 
periods (:/OREMPs) in narcoleptic patients on the 
other (Vogel 1960). the question arises as to whether 
there is a direct link between DR2 and certain features 
of sleep structure. The aim of the present study was, 
therefore, to look for HLA-DR2 incidence in depres- 
sion, an illness that shares--even though less regu- 
larly--tbe feature of shortened REM latency with 
narcolepsy (Coble et al 1981). 
Recently Montplaisir et al (1990) failed Lo show 
an increased occurrence of HLA-DR2 in unil.~,olar 
depression, as against Riemann et al. (1988), wko in 
a pilot study, reported 4 of 7 patients with a ,valor 
depressive disorder and at least one SOREMP &:ring 
night sleep to be HLA-DR2 positive. A possible ex- 
planation for these conflicting results could be a 
depression-independent impact o~ HLA-DR2 on sleep 
sh~cture. We, therefore, examined the frequency of 
HLA-DR2 in a larger sample of depressed patients, 
res*cfing our post hoc examination to those depres- 
sives who displayed SOREMPs in standard night po- 
lysomno~raphy ~md, thereby, share this typical sleep 
Sixteen patients (8 men and 8 women) with a 
major depressive disorder/endogenous s btype (Re- 
search Diagnostic Criteria, RDC) (Spitzer et al 1978) 
were investigated, all giving informed consent. The 
mean age (_+SD) was 47.3 ± 7.5 years. ,'~i~een of 
the patients under investigation displayed a SOREMP 
(REM sleep latency after first epoch $2 sleep <15 
min) at least once during night sleep recordings, 
whereas the other 3 patients exhibited REM latencies 
of 18, 21, and 23 min. 
On the average, one or two nights of baseline sleep 
were recorded for each patient, applying standard 
night sonmopolygraphy (EEG, EMG, EOG). PatieWs 
were free of any psychoactive medication at least 1 
week prior to sleep recordings; urinary drug moni- 
toring was carried out ~gularly. Sleep recordings and 
analysis were carried out according to the guidelines 
proposed by Rechtschaffen and Kales (1968). The 
following sleep parameters were determined: sleep 
period time (SPT); sleep onset latency (min, defined 
as first epoch $2 sleep); REM sleep latency (rain, 
defined as the time interval between sleep onset and 
REM start); sleep efficiency (%); and the percentages 
for gEM and slow wave sleep ($3 + $4), both based 
on SFr. HLA-typing was determined by duplicate 
serological testing and by reslrictioa fragment length 
polymorphism (RFLP) analysis (cf. Geisler and Al- 
bert 1989). 
Concerning our target variable, mean REM la- 
tency (+ SD) was 10.6 _ 6.4 nfia. An~ysis of ",he 
other sleep parameters evealed alow sleep efficiency 
(72.1% + 20.1%), a rather long sleep onset latency 
(27.8 min +_ 18.5 min), a normal amount ef ~.EM 
sleep (23.6% -+ 9.7%), and a low percentage ofslow- 
wave sleep (6.8 -+ 6.7% SPT). HLA typing reve~ed 
an incidence of HLA-DR2 cf25% (or 4 of 16 patients 
under investigation). 
In our subgroup of depressed patients, showing 
at least one ~OP.~,MP during polyg~ap,hic sleep re- 
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cording, the incidence of HLA-DR2 was only 25%. 
This observation strongly underlines the findings of 
Mentplaisk et al (!990) that the frequency of HLA- 
DR2 in depressed patients in general is not different 
from that found in normal controls. Furthermore, our 
results clearly refute the assumption of a direct im- 
munogenetic association between abbreviated REM- 
sleep latency (including SOREI:dPs) and HLA-DR2. 
Finally, the present results are in agreement with 
previous findings showing that REM latency in nor- 
real subjects does not correlate with the HLA-DR2 
haplotype (Schulz et al 1987). 
From this evidence we conclude that the presence 
of HLA-DR2 and an increased propensity toward SO- 
REMPs are two independent features. This suggests 
that HLA-DR2 may be instead associated with ca- 
taplexy, a pathophysiological event that is peculiar 
to narcolepsy (Guilleminault 1976), and ttmt has never 
been reported for depressives or other subjects ~,ith 
shortened REM latency. 
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